$WVE

Wagner Heidi L sold $42K of WVE

Wagner Heidi L sold 7,000 shares of Wave Life Sciences, Inc. (WVE) at $6.01 on 2026-08-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Wagner Heidi L
Published Aug 14, 2026, 1:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 1:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$WVE
Neutral
high confidence
Mentioned
$WVE
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$WVENeutralLow
01

Why it matters

The newest disclosed fact is the director’s sale size, price, and post-transaction holdings under a 10b5-1 plan; no new corporate event is described.

02

Market read

Traders may note the sale for sentiment monitoring, but there is no fundamental catalyst or guidance change in the text.

03

What to watch

Insider sales are common and often scheduled; without changes in other insiders, volume, or company disclosures, the trading signal is weak.

Relevance 2/10Novelty 2/10Timing: SEC Form 4 filed 2026-08-13, transaction dated 2026-08-11

Background

The article is an SEC Form 4 insider transaction disclosure for Wave Life Sciences, Inc.

Company-level read

Ticker impact

$WVENeutralHigh confidence
Context

Wave Life Sciences director Wagner Heidi L sold 7,000 shares at $6.01 under a pre-arranged 10b5-1 plan, per Form 4.

Expected impact

Low likelihood of a sustained price move solely from this Form 4 sale.

Evidence & confidence

The filing is an open-market sale by a director, explicitly under a pre-arranged 10b5-1 plan, with no accompanying operational or guidance change disclosed.

Market effects

No sector-level implications; this is company-specific insider transaction reporting.

None indicated.

None indicated.

Counterpoint

A director sale can still reflect private information, but the presence of a 10b5-1 plan reduces interpretability.

Key entities

  • Wave Life Sciences, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Wagner Heidi L

    Director who sold 7,000 shares at $6.0100/share under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$WVEMedAI 8/10

Wave Life Sciences Ltd.: Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity

Wave Life Sciences (WVE) initiated a Phase 2a trial for WVE-007, its investigational GalNAc-siRNA, in combination with tirzepatide for obesity treatment. The trial aims to evaluate the combination therapy's efficacy in adults with obesity and type 2 diabetes. Wave also plans to initiate a maintenance trial for WVE-007 in the second half of 2026. Preclinical data suggest WVE-007 could enhance fat loss and preserve muscle when combined with GLP-1 therapies.

$WVEMed

Wave Life Sciences Ltd. (WVE): Results of Operations and Financial Condition

Wave Life Sciences Ltd. (WVE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update Dosing underway in Phase 2a multidose portion of the INLIGHT TM trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with obesity (BMI: 35-50 kg/m 2 ) and comorbidities; tri